Phosphatidylinositol 3-kinase (PI3Kα)/AKT axis blockade with taselisib or ipatasertib enhances the efficacy of anti-microtubule drugs in human breast cancer cells

PURPOSE: The Phosphatidylinositol 3-kinase (PI3Ks) pathway is commonly altereted in breast cancer patients, but its role is still unclear. Taselisib, a mutant PI3Kα selective inhibitor, and ipatasertib, an AKT inhibitor, are currently under investigation in clinical trials in combination with paclit...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgillo, Floriana, Della Corte, Carminia Maria, Diana, Anna, Mauro, Concetta di, Ciaramella, Vincenza, Barra, Giusi, Belli, Valentina, Franzese, Elisena, Bianco, Roberto, Maiello, Evaristo, de Vita, Ferdinando, Ciardiello, Fortunato, Orditura, Michele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652721/
https://www.ncbi.nlm.nih.gov/pubmed/29100327
http://dx.doi.org/10.18632/oncotarget.20385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5652721/
https://www.ncbi.nlm.nih.gov/pubmed/29100327
http://dx.doi.org/10.18632/oncotarget.20385

Ejemplares similares